Mechanism of HPD-Mediated Glycolytic Reprogramming in Ovarian Cancer
International Journal of Biology and Life Sciences · 10.07.2026 · 15 (2) · 62-69
DOI: 10.54097/5w7y7r24 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biology and Life Sciences, online erschienen am 10.07.2026. Verfasst von Siyu Xu. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Ovarian cancer is hard to diagnose at an early stage and has a high rate of recurrence. Because of this, its clinical treatment faces serious challenges. In recent years, studies have found that metabolic reprogramming, especially the abnormal activation of glycolysis, plays a key role in the progression of ovarian cancer. 4-Hydroxyphenylpyruvate dioxygenase (HPD) is an important molecule with two functions. It acts both as a metabolic enzyme and as an RNA-binding protein. Recent studies have confirmed that HPD is abnormally expressed in many tumors and is involved in the regulation of malignant behavior. This paper systematically reviews the molecular mechanism of HPD as an RNA-binding protein. HPD recognizes the RRACH motif on target mRNAs and promotes the translation of the key glycolytic enzymes TPI and ENO1. As a result, it increases glycolytic flux and cell proliferation in ovarian cancer cells. This paper also summarizes the potential therapeutic value of the small-molecule HPD inhibitor NTBC and its combined use with paclitaxel. These findings provide a new theoretical basis and new strategic directions for the precise treatment of ovarian cancer.
Zitieren
APA
Xu, S. (2026). Mechanism of HPD-Mediated Glycolytic Reprogramming in Ovarian Cancer. International Journal of Biology and Life Sciences, 15(2), 62-69. https://doi.org/10.54097/5w7y7r24
Vancouver
Xu S. Mechanism of HPD-Mediated Glycolytic Reprogramming in Ovarian Cancer. International Journal of Biology and Life Sciences. 2026;15(2):62-69. doi:10.54097/5w7y7r24
BibTeX
@article{Xu2026,
author = {Xu, Siyu},
title = {Mechanism of HPD-Mediated Glycolytic Reprogramming in Ovarian Cancer},
journal = {International Journal of Biology and Life Sciences},
year = {2026},
volume = {15},
number = {2},
pages = {62--69},
doi = {10.54097/5w7y7r24}
}
EUVIMED